For adult patients with relapsed or refractory CLL or SLL after at least 2 prior therapies

POWER PRECISION

The FIRST AND ONLY oral dual PI3K-δ and PI3K-γ inhibitor

CLL, chronic lymphocytic leukemia; δ, delta; γ, gamma; PI3K, phosphoinositide 3-kinase;

SLL, small lymphocytic lymphoma.